Gyre Therapeutics
GYRE
41 hedge funds and large institutions have $14.2M invested in Gyre Therapeutics in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 17 reducing their positions, and 9 closing their positions.
24,596% more call options, than puts
Call options by funds: $6.67M | Put options by funds: $27K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 43 → 41 (-2)
5.3% less ownership
Funds ownership: 30.83% → 25.52% (-5.3%)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
42% less capital inflows, than outflows
Capital inflows: $1.34M | Capital outflows: $2.31M
82% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Madison Avenue Partners
New York
|
+$892K |
| 2 |
Nantahala Capital Management
New Canaan,
Connecticut
|
+$297K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$67.2K |
| 4 |
Virtu Financial
New York
|
+$47.8K |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$18.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$871K |
| 2 |
Renaissance Technologies
New York
|
-$330K |
| 3 |
Ikarian Capital
Dallas,
Texas
|
-$314K |
| 4 |
Millennium Management
New York
|
-$266K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$100K |
GYRE Hedge Fund Activity: Q2 2022 in Review
41 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q2 2022, worth a combined $14.2M — up 122% from $6.39M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of GYRE and 7 opened new positions — a net loss of 2 holders — while 17 trimmed existing stakes and 3 added.
The largest buyer was Madison Avenue Partners, opening a new position worth an estimated $892K. The largest seller was Sabby Management, exiting entirely with an estimated $871K sold.
- 41 institutional investors held Gyre Therapeutics (GYRE) as of Q2 2022, down from 43 in Q1 2022.
- Funds reported $14.2M of Gyre Therapeutics stock for Q2 2022, up 122% quarter-over-quarter.
- 7 funds opened new Gyre Therapeutics positions in Q2 2022 and 9 closed out, a net change of -2 holders.
- The largest Gyre Therapeutics buyer in Q2 2022 was Madison Avenue Partners, an estimated $892K added.
- The largest Gyre Therapeutics seller in Q2 2022 was Sabby Management, an estimated $871K sold.
Based on aggregated 13F filings for Q2 2022.